These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 11709343

  • 1. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.
    Woyke T, Pettit GR, Winkelmann G, Pettit RK.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3580-4. PubMed ID: 11709343
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
    Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Ludueña RF, Hamel E.
    Biochem Pharmacol; 1993 Apr 06; 45(7):1503-15. PubMed ID: 8471072
    [Abstract] [Full Text] [Related]

  • 3. Differential gene expression in auristatin PHE-treated Cryptococcus neoformans.
    Woyke T, Berens ME, Hoelzinger DB, Pettit GR, Winkelmann G, Pettit RK.
    Antimicrob Agents Chemother; 2004 Feb 06; 48(2):561-7. PubMed ID: 14742210
    [Abstract] [Full Text] [Related]

  • 4. Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans.
    Woyke T, Roberson RW, Pettit GR, Winkelmann G, Pettit RK.
    Antimicrob Agents Chemother; 2002 Dec 06; 46(12):3802-8. PubMed ID: 12435680
    [Abstract] [Full Text] [Related]

  • 5. Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans.
    Pettit RK, Pettit GR, Hazen KC.
    Antimicrob Agents Chemother; 1998 Nov 06; 42(11):2961-5. PubMed ID: 9797233
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
    Bai RL, Pettit GR, Hamel E.
    Biochem Pharmacol; 1990 Oct 15; 40(8):1859-64. PubMed ID: 2242019
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A.
    Clin Cancer Res; 1998 May 15; 4(5):1337-43. PubMed ID: 9607595
    [Abstract] [Full Text] [Related]

  • 8. Antineoplastic agents 365. Dolastatin 10 SAR probes.
    Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, Pettit RK, Hogan F, Bai R, Chapuis JC, McAllister SC, Schmidt JM.
    Anticancer Drug Des; 1998 Jun 15; 13(4):243-77. PubMed ID: 9627667
    [Abstract] [Full Text] [Related]

  • 9. Postantifungal effect methods.
    Vitale RG.
    Methods Mol Med; 2005 Jun 15; 118():153-8. PubMed ID: 15888941
    [Abstract] [Full Text] [Related]

  • 10. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
    Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC.
    Int J Oncol; 2007 Aug 15; 31(2):353-60. PubMed ID: 17611692
    [Abstract] [Full Text] [Related]

  • 11. Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes.
    Vitale RG, Afeltra J, Meis JF, Verweij PE.
    Mycoses; 2007 Jul 15; 50(4):270-6. PubMed ID: 17576318
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media.
    Vitale RG, Meis JF, Mouton JW, Verweij PE.
    J Antimicrob Chemother; 2003 Jul 15; 52(1):65-70. PubMed ID: 12775672
    [Abstract] [Full Text] [Related]

  • 13. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
    Fennell BJ, Carolan S, Pettit GR, Bell A.
    J Antimicrob Chemother; 2003 Apr 15; 51(4):833-41. PubMed ID: 12654761
    [Abstract] [Full Text] [Related]

  • 14. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A.
    Anticancer Drugs; 1998 Feb 15; 9(2):149-56. PubMed ID: 9510501
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
    Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FW, Pettit GR, Al-Katib A.
    Int J Oncol; 1999 Aug 15; 15(2):367-72. PubMed ID: 10402249
    [Abstract] [Full Text] [Related]

  • 17. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Durkin KP, Boyd MR, Bai R, Hamel E, Schmidt JM, Chapuis JC.
    Anticancer Drug Des; 1995 Oct 15; 10(7):529-44. PubMed ID: 7495477
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro postantifungal effect, adhesion traits and haemolysin production of Candida dubliniensis isolates following exposure to 5-fluorocytosine.
    Ellepola AN, Chandy R, Khan ZU.
    Mycoses; 2015 Sep 15; 58(9):536-43. PubMed ID: 26201447
    [Abstract] [Full Text] [Related]

  • 20. Antifungal and cancer cell growth inhibitory activities of 1-(3',4',5'-trimethoxyphenyl)-2-nitro-ethylene.
    Pettit RK, Hamel E, Verdier-Pinard P, Roberson RW, Hazen KC, Pettit GR, Crews LC.
    Mycoses; 2002 Apr 15; 45(3-4):65-74. PubMed ID: 12000503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.